Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is 10.48% higher on its value in year-to-date trading and has touched a low of $99.06 and a high of $148.06 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The JAZZ stock was last observed hovering at around $134.16 in the last trading session, with the day’s gains setting it 1.89%.
Currently trading at $136.05, the stock is -1.42% and 5.42% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.06 million and changing 1.41% at the moment leaves the stock 16.47% off its SMA200. JAZZ registered 16.65% gain for a year compared to 6-month gain of 27.03%. The firm has a 50-day simple moving average (SMA 50) of $129.0544 and a 200-day simple moving average (SMA200) of $116.8088.
The stock witnessed a 4.67% loss in the last 1 month and extending the period to 3 months gives it a 12.62%, and is -0.29% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.74% over the week and 3.35% over the month.
Jazz Pharmaceuticals plc (JAZZ) has around 2800 employees, a market worth around $8.26B and $4.07B in sales. Current P/E ratio is 15.55 and Fwd P/E is 5.85. Profit margin for the company is 13.77%. Distance from 52-week low is 37.34% and -8.11% from its 52-week high. The company has generated returns on investments over the last 12 months (5.48%).
The EPS is expected to grow by 12.00% this year
705.0 institutions hold shares in Jazz Pharmaceuticals plc (JAZZ), with institutional investors hold 103.00% of the company’s shares. The shares outstanding are 60.63M, and float is at 57.97M with Short Float at 7.53%. Institutions hold 99.82% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.32 million shares valued at $674.82 million. The investor’s holdings represent 10.1103 of the JAZZ Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.15 million shares valued at $655.94 million to account for 9.8274 of the shares outstanding. The other top investors are LSV ASSET MANAGEMENT which holds 2.48 million shares representing 3.9448 and valued at over $264.75 million, while STATE STREET CORP holds 3.2258 of the shares totaling 2.02 million with a market value of $215.31 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
The most recent transaction is an insider sale by Iannone Robert, the company’s EVP, Global Head of R&D & CMO. SEC filings show that Iannone Robert sold 2,403 shares of the company’s common stock on Mar 10 ’25 at a price of $138.41 per share for a total of $0.33 million. Following the sale, the insider now owns 79621.0 shares.
Jazz Pharmaceuticals plc disclosed in a document filed with the SEC on Mar 10 ’25 that Carr Patricia (SVP, Chief Accounting Officer) sold a total of 1,140 shares of the company’s common stock. The trade occurred on Mar 10 ’25 and was made at $137.81 per share for $0.16 million. Following the transaction, the insider now directly holds 7012.0 shares of the JAZZ stock.
Still, SEC filings show that on Mar 10 ’25, Iannone Robert (Officer) Proposed Sale 1,767 shares at an average price of $145.00 for $0.26 million. The insider now directly holds shares of Jazz Pharmaceuticals plc (JAZZ).
